文献速递甲状腺疾病

甲状腺功能亢进患者肝功能检查异常:系统综述与荟萃分析

Abnormal Liver Blood Tests in Patients with Hyperthyroidism: Systematic Review and Meta-Analysis.
PubMed 文献 · Thyroid · 2021-01-21

该系统综述与荟萃分析纳入25项研究,评估新诊断且无并发症的甲亢患者肝功能检查(LBT)异常的患病率及抗甲状腺药物(ATD)治疗后的恢复情况。结果显示,未治疗甲亢患者至少一项LBT异常的患病率为55%,Graves病患者为60%;ATD治疗并恢复甲状腺功能正常后,转氨酶异常多可恢复正常。

要点

  • 未治疗甲亢患者至少一项肝功能指标异常的患病率为55%。
  • ATD治疗后转氨酶异常恢复正常比例较高(ALT 83%,AST 87%)。
  • 甲亢初诊时肝功能异常常见,需结合ATD治疗随访鉴别。

核心结论

  • 肝功能检查异常在新诊断未治疗甲亢中常见。
  • ATD治疗使甲亢患者转氨酶升高(最高达正常上限五倍)有较高安全恢复正常的可能。

研究设计与样本

  • 系统综述与荟萃分析,检索2286项研究,最终纳入25项。
  • 采用随机效应模型进行比例荟萃分析,用I2统计量量化异质性。

主要发现

  • 未治疗甲亢患者至少一项LBT异常的患病率为55%(95%CI 46-63%,I2 96%)。
  • Graves病患者至少一项LBT异常的患病率为60%(95%CI 53-67%,I2 92%)。
  • 甲亢患者ALT、AST、ALP、BIL、GGT异常患病率分别为33%(95%CI 24-44%)、23%(95%CI 17-29%)、44%(95%CI 35-52%)、12%(95%CI 7-20%)、24%(95%CI 16-36%)。
  • ATD治疗并恢复甲状腺功能正常后,ALT、AST、ALP、BIL、GGT异常恢复正常比例分别为83%(95%CI 72-90%)、87%(95%CI 74-94%)、53%(95%CI 32-73%)、50%(CI无法计算)、70%(95%CI 47-87%)。

关键数值与推荐

  • 未治疗甲亢患者至少一项LBT异常患病率55%(95%CI 46-63%)。
  • Graves病患者至少一项LBT异常患病率60%(95%CI 53-67%)。
  • ATD治疗后ALT异常恢复比例83%(95%CI 72-90%),AST恢复比例87%(95%CI 74-94%)。

临床怎么用

  • 甲亢初诊时应评估肝功能,ATD治疗过程中需监测LBT变化。
  • 转氨酶升高至正常上限五倍以内时,ATD治疗下恢复正常的可能性较高。

局限性

  • 各项结局异质性较高(I2最高达96%)。
  • BIL异常恢复比例的置信区间无法计算。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Abnormal liver blood tests (LBTs) in hyperthyroid patients are not uncommonly encountered. One major adverse event of antithyroid drug (ATD) therapy is drug-induced hepatotoxicity. Abnormal LBT in the hyperthyroidism scenario is a main diagnostic and therapeutic dilemma. We aimed to assess the prevalence and the response to ATD therapy of LBT abnormalities in newly diagnosed and uncomplicated hyperthyroidism through a systematic review and meta-analysis. Methods: A literature search was performed reporting LBTs at presentation and after ATD therapy in hyperthyroid patients. A proportion meta-analysis was performed with random-effects model. Pooled data were presented with 95% confidence intervals (CI). I2 statistic index was used to quantify the heterogeneity. Sensitivity analyses for prevalence of hyperthyroid patients with at least one abnormal LBT were performed. p-Value of <0.05 was regarded as significant. Results: The literature search yielded 2286 studies, of which 25 were included for systematic review and meta-analysis. The prevalence of untreated hyperthyroid and Graves' disease patients with at least one abnormal LBT was 55% ([CI 46-63%], I2 96%) and 60% ([CI 53-67%], I2 92%), respectively. The prevalence of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), total bilirubin (BIL), and γ-glutamyltransferase (GGT) abnormalities in hyperthyroid patients were 33% ([CI 24-44%], I2 95%), 23% ([CI 17-29%], I2 89%), 44% ([CI 35-52%], I2 93%), 12% ([CI 7-20%], I2 92%), and 24% ([CI 16-36%], I2 95%), respectively. ATD therapy, along with euthyroidism restoration, was accompanied by normalization of LBT abnormalities in the following percentage of cases: ALT 83% ([CI 72-90%], I2 46%), AST 87% ([CI 74-94%], I2 2%), ALP 53% ([CI 32-73%], I2 76%), BIL 50% (CI cannot be calculated), and GGT 70% ([CI 47-87%], I2 74%). The sensitivity analyses showed similar results as those of the main analyses. The publication bias was not statistically significant for all outcomes, except for the prevalence of resolved BIL abnormalities that was not calculable. Conclusions: LBT abnormalities are common in newly diagnosed and untreated hyperthyroidism setting. A high chance of safely normalizing elevated transaminases, up to fivefold above the upper limit of normal, accompanies the use of ATDs in the treatment of hyperthyroidism.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Scappaticcio L, Longo M, Maiorino MI, et al. Abnormal Liver Blood Tests in Patients with Hyperthyroidism: Systematic Review and Meta-Analysis. Thyroid. 2021. PMID: 33327837. doi:10.1089/thy.2020.0715

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。